1309 related articles for article (PubMed ID: 34757006)
1. Post-acute COVID-19 syndrome after reinfection and vaccine breakthrough by the SARS-CoV-2 Gamma variant in Brazil.
Penetra SLS; da Silva MFB; Resende P; Pina-Costa A; Santos HFP; Guaraldo L; Calvet GA; Ogrzewalska M; Arantes I; Zukeram K; de Araújo MF; Lima ABM; Lopes RS; Lira-Silva LR; Moraes IV; Wakimoto MD; Fuller TL; Gabaglia CR; Espíndola OM; Bonaldo MC; Daniel-Ribeiro CT; Whitworth J; Smith C; Nielsen-Saines K; Pauvolid-Correa A; Siqueira MM; Brasil P
Int J Infect Dis; 2022 Jan; 114():58-61. PubMed ID: 34757006
[TBL] [Abstract][Full Text] [Related]
2. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination.
Chen LL; Lu L; Choi CY; Cai JP; Tsoi HW; Chu AW; Ip JD; Chan WM; Zhang RR; Zhang X; Tam AR; Lau DP; To WK; Que TL; Yip CC; Chan KH; Cheng VC; Yuen KY; Hung IF; To KK
Clin Infect Dis; 2022 May; 74(9):1623-1630. PubMed ID: 34309648
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea.
Nham E; Ko JH; Song KH; Choi JY; Kim ES; Kim HJ; Kim B; Lim HY; Kim KC; Jang HC; Lee KH; Song YG; Baek YJ; Ahn JY; Choi JY; Kim YC; Park YS; Choi WS; Bae S; Kim SH; Kang ES; Jeong HW; Kim SW; Kwon KT; Kim SS; Peck KR
Front Immunol; 2022; 13():968105. PubMed ID: 36211416
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
[TBL] [Abstract][Full Text] [Related]
5. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 vaccine breakthrough reinfection in a health-care worker of Iraq: A case report.
Hasan DA; Maulud SQ; Jalal PJ; Priyanka ; Choudhary OP
Hum Vaccin Immunother; 2022 Nov; 18(5):2055947. PubMed ID: 35417318
[TBL] [Abstract][Full Text] [Related]
7. Severe SARS-CoV-2 Breakthrough Reinfection With Delta Variant After Recovery From Breakthrough Infection by Alpha Variant in a Fully Vaccinated Health Worker.
Shastri J; Parikh S; Aggarwal V; Agrawal S; Chatterjee N; Shah R; Devi P; Mehta P; Pandey R
Front Med (Lausanne); 2021; 8():737007. PubMed ID: 34490316
[No Abstract] [Full Text] [Related]
8. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
[TBL] [Abstract][Full Text] [Related]
9. Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant.
Villas-Boas LS; Paula AV; Silva ARD; Paiao HGO; Tozetto-Mendoza TR; Manuli ER; Leal FE; Ferraz ABC; Sabino EC; Bierrenbach AL; Witkin SS; Mendes-Correa MC
Clinics (Sao Paulo); 2022; 77():100068. PubMed ID: 35767900
[TBL] [Abstract][Full Text] [Related]
10. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
11. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
Schuh AJ; Satheshkumar PS; Dietz S; Bull-Otterson L; Charles M; Edens C; Jones JM; Bajema KL; Clarke KEN; McDonald LC; Patel S; Cuffe K; Thornburg NJ; Schiffer J; Chun K; Bastidas M; Fernando M; Petropoulos CJ; Wrin T; Cai S; Adcock D; Sesok-Pizzini D; Letovsky S; Fry AM; Hall AJ; Gundlapalli AV
Microbiol Spectr; 2022 Aug; 10(4):e0124722. PubMed ID: 35856710
[TBL] [Abstract][Full Text] [Related]
13. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
Loconsole D; Sallustio A; Accogli M; Leaci A; Sanguedolce A; Parisi A; Chironna M
Clin Microbiol Infect; 2021 Aug; 27(8):1174.e1-1174.e4. PubMed ID: 33984489
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies.
Brehm TT; Pfefferle S; von Possel R; Kobbe R; Nörz D; Schmiedel S; Grundhoff A; Olearo F; Emmerich P; Robitaille A; Günther T; Braun P; Andersen G; Knobloch JK; Addo MM; Lohse AW; Aepfelbacher M; Fischer N; Schulze Zur Wiesch J; Lütgehetmann M
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921216
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 intra-host diversity, antibody response, and disease severity after reinfection by the variant of concern Gamma in Brazil.
Naveca FG; Nascimento VA; Nascimento F; Ogrzewalska M; Pauvolid-Corrêa A; Araújo MF; Arantes I; Batista ÉR; Magalhães AÁ; Vinhal F; Mattos TP; Riediger I; Debur MDC; Grinsztejn B; Veloso VG; Brasil P; Rodrigues RR; Rovaris DB; Fernandes SB; Fernandes C; Santos JHA; Abdalla LF; Costa-Filho R; Silva M; Souza V; Costa ÁA; Mejía M; Brandão MJ; Gonçalves LF; Silva GA; de Jesus MS; Pessoa K; Corado ALG; Duarte DCG; Machado AB; Zukeram KA; Valente N; Lopes RS; Pereira EC; Appolinario LR; Rocha AS; Tort LFL; Sekizuka T; Itokawa K; Hashino M; Kuroda M; Dezordi FZ; Wallau GL; Delatorre E; Gräf T; Siqueira MM; Bello G; Resende PC
Sci Rep; 2023 May; 13(1):7306. PubMed ID: 37147348
[TBL] [Abstract][Full Text] [Related]
16. Early detection of SARS-CoV-2 P.1 variant in Southern Brazil and reinfection of the same patient by P.2.
Silva MSD; Demoliner M; Hansen AW; Gularte JS; Silveira F; Heldt FH; Filippi M; Pereira VMAG; Silva FPD; Mallmann L; Fink P; Silva LLD; Weber MN; Almeida PR; Fleck JD; Spilki FR
Rev Inst Med Trop Sao Paulo; 2021; 63():e58. PubMed ID: 34231823
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
18. A 48-Year-Old Immunocompetent Female Resident of Southern Florida with Confirmed Reinfection with P.1 (Gamma) Variant of SARS-CoV-2.
Kim M; Poon KK; Miller N; Rubio-Gomez H
Am J Case Rep; 2022 Jan; 23():e935329. PubMed ID: 35041639
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection.
Uriu K; Cárdenas P; Muñoz E; Barragan V; Kosugi Y; Shirakawa K; Takaori-Kondo A; ; Sato K
J Infect Dis; 2022 Sep; 226(7):1200-1203. PubMed ID: 35176774
[TBL] [Abstract][Full Text] [Related]
20. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
